mavishhs personal page - To The Moon

mavishhs

mavishhs

No personal profile

30Follow

15Followers

0Topic

0Badge

2021-09-18

Great ariticle, would you like to share it?

Sorry, the original content has been removed

2021-04-26

$Lion-OCBC Sec HSTECH S$(HST.SI)$how do you think this will going to how much in future 6mth?

2021-04-20

Great ariticle, would you like to share it?

Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate

2021-04-07

hmmm

Sorry, the original content has been removed

2021-04-07

$Tiger Brokers(TIGR)$like my post old haha

2021-03-23

$Mogo Finance Technology Inc.(MOGO)$like me pls

2021-03-09

[OK] [OK] [OK] gogo

2021-03-04

$Tiger Brokers(TIGR)$rest , ready to go

2021-03-01

Great ariticle, would you like to share it?

Exxon Soars After Activists Jeff Ubben, Michael Angelakis Join Board Of Directors

2021-02-25

hmmmm

Sorry, the original content has been removed

2021-02-23

[OK] [OK] [OK] [OK]

2021-02-23

Great ariticle, would you like to share it?

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3570762430883798","uuid":"3570762430883798","gmtCreate":1607669310477,"gmtModify":1610530257149,"name":"mavishhs","pinyin":"mavishhs","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":15,"headSize":30,"tweetSize":72,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":884250657,"gmtCreate":1631896562979,"gmtModify":1676530665723,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884250657","repostId":"884264656","repostType":1,"isVote":1,"tweetType":1,"viewCount":2316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374051734,"gmtCreate":1619403768828,"gmtModify":1704723308172,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","listText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","text":"$Lion-OCBC Sec HSTECH S$(HST.SI)$how do you think this will going to how much in future 6mth?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374051734","isVote":1,"tweetType":1,"viewCount":2217,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":371159511,"gmtCreate":1618922729333,"gmtModify":1704716907339,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/371159511","repostId":"2128947843","repostType":4,"repost":{"id":"2128947843","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1618914723,"share":"https://ttm.financial/m/news/2128947843?lang=&edition=fundamental","pubTime":"2021-04-20 18:32","market":"us","language":"en","title":"Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2128947843","media":"Benzinga","summary":"Johnson &amp; Johnson (NYSE:JNJ) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.34 by 10.68 percent. This is a 12.61 percent increase over earnings of $2.30 per share from the","content":"<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-20 18:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2128947843","content_text":"Johnson & Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.Johnson & Johnson Reports 2021 First-Quarter Results:- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpointFIRST-QUARTER 2021 SEGMENT COMMENTARY:Consumer HealthConsumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.  Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.PharmaceuticalPharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.Medical DevicesMedical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2206,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3557227905112544","authorId":"3557227905112544","name":"ShaunVee","avatar":"https://static.tigerbbs.com/5f64fe4fcaa4f1d2aedde844df964cb4","crmLevel":11,"crmLevelSwitch":0,"idStr":"3557227905112544","authorIdStr":"3557227905112544"},"content":"Vaccine are here to stay, they gonna earn more money In near future i guess..","text":"Vaccine are here to stay, they gonna earn more money In near future i guess..","html":"Vaccine are here to stay, they gonna earn more money In near future i guess.."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341976026,"gmtCreate":1617776262465,"gmtModify":1704702986356,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmm","listText":"hmmm","text":"hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341976026","repostId":"1162389133","repostType":4,"isVote":1,"tweetType":1,"viewCount":2221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341062059,"gmtCreate":1617762689971,"gmtModify":1704702790323,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","text":"$Tiger Brokers(TIGR)$like my post old haha","images":[{"img":"https://static.tigerbbs.com/d6460bc8111d6b40363d22d3f8a2998a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341062059","isVote":1,"tweetType":1,"viewCount":2115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":353460824,"gmtCreate":1616513437568,"gmtModify":1704795188865,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","listText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","text":"$Mogo Finance Technology Inc.(MOGO)$like me pls","images":[{"img":"https://static.tigerbbs.com/d1eabf3a50dad90af4a39bd7c5db8334","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353460824","isVote":1,"tweetType":1,"viewCount":2226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":323944336,"gmtCreate":1615301275425,"gmtModify":1704780842618,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","text":"[OK] [OK] [OK] gogo","images":[{"img":"https://static.tigerbbs.com/0186365c81b90e76d6a42357df7326ed","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323944336","isVote":1,"tweetType":1,"viewCount":1640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":364902905,"gmtCreate":1614789063307,"gmtModify":1704775350744,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","text":"$Tiger Brokers(TIGR)$rest , ready to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/364902905","isVote":1,"tweetType":1,"viewCount":1938,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362819137,"gmtCreate":1614611789329,"gmtModify":1704773099898,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362819137","repostId":"1161689985","repostType":4,"repost":{"id":"1161689985","kind":"news","pubTimestamp":1614607057,"share":"https://ttm.financial/m/news/1161689985?lang=&edition=fundamental","pubTime":"2021-03-01 21:57","market":"us","language":"en","title":"Exxon Soars After Activists Jeff Ubben, Michael Angelakis Join Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=1161689985","media":"zerohedge","summary":"Could Exxon wind up being the next ESG play?Shares of the oil and gas giant spiked Monday pre-market","content":"<blockquote><i>Could Exxon wind up being the next ESG play?</i></blockquote><p>Shares of the oil and gas giant spiked Monday pre-market after CNBC's David Faberreportedthat Jeff Ubben would be joining the company's board. In addition, Mike Angelakis - the former CFO of Comcast and a \"green\" activist - was also said to be joining the board.</p><p>\"Mike Angelakis, the chairman and chief executive officer of Atairos and former CFO of Comcast, is also joining the board,\" CNBCreported. According toAngelakis' bio, he \"was the Chairman of the Board for the Federal Reserve Bank of Philadelphia, a member of the Board of Directors of Duke Energy and Hewlett Packard Enterprises, and a trustee of Babson College.\"</p><p><img src=\"https://static.tigerbbs.com/c92e9846f3d968f06284115d27d81ad4\" tg-width=\"500\" tg-height=\"283\" referrerpolicy=\"no-referrer\">Two weeks agowe notedthat Ubben was looking to raise another $8 billion for his impact fund.&nbsp;Ubben was looking to raise the capital for his Spring Fund II, a successor to his $1.5 billion Spring Fund that he started while at ValueAct, which he founded in 2000, according to&nbsp;Bloomberg. The goal of the fund was reportedly going to be looking at \"impact investing\", which aims to \"make systemic changes at companies and sectors to the betterment of society.\" As we said at the time:</p><blockquote>This, of course, would fit nicely if Ubben was looking to make a major operational, ideological (and PR) shift at an undervalued legacy oil and gas company like Exxon.</blockquote><p>In early February&nbsp;we reported&nbsp;that Ubben was considering a \"meaningful stake\" in Exxon and could, as a result, even wind up with a seat on the board.</p><p><img src=\"https://static.tigerbbs.com/9b33f78346c34b0c6700782c224446fc\" tg-width=\"500\" tg-height=\"328\" referrerpolicy=\"no-referrer\"></p><p>Ubben left ValueAct last year to start his own firm that is focused on investments in social and environmental issues.</p><p><img src=\"https://static.tigerbbs.com/df87a1333f12dd2e677999e333de1888\" tg-width=\"1084\" tg-height=\"496\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exxon Soars After Activists Jeff Ubben, Michael Angelakis Join Board Of Directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExxon Soars After Activists Jeff Ubben, Michael Angelakis Join Board Of Directors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-01 21:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/exxon-spikes-after-cnbc-reports-jeff-ubben-join-board-directors><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Could Exxon wind up being the next ESG play?Shares of the oil and gas giant spiked Monday pre-market after CNBC's David Faberreportedthat Jeff Ubben would be joining the company's board. In addition, ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/exxon-spikes-after-cnbc-reports-jeff-ubben-join-board-directors\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"source_url":"https://www.zerohedge.com/markets/exxon-spikes-after-cnbc-reports-jeff-ubben-join-board-directors","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161689985","content_text":"Could Exxon wind up being the next ESG play?Shares of the oil and gas giant spiked Monday pre-market after CNBC's David Faberreportedthat Jeff Ubben would be joining the company's board. In addition, Mike Angelakis - the former CFO of Comcast and a \"green\" activist - was also said to be joining the board.\"Mike Angelakis, the chairman and chief executive officer of Atairos and former CFO of Comcast, is also joining the board,\" CNBCreported. According toAngelakis' bio, he \"was the Chairman of the Board for the Federal Reserve Bank of Philadelphia, a member of the Board of Directors of Duke Energy and Hewlett Packard Enterprises, and a trustee of Babson College.\"Two weeks agowe notedthat Ubben was looking to raise another $8 billion for his impact fund. Ubben was looking to raise the capital for his Spring Fund II, a successor to his $1.5 billion Spring Fund that he started while at ValueAct, which he founded in 2000, according to Bloomberg. The goal of the fund was reportedly going to be looking at \"impact investing\", which aims to \"make systemic changes at companies and sectors to the betterment of society.\" As we said at the time:This, of course, would fit nicely if Ubben was looking to make a major operational, ideological (and PR) shift at an undervalued legacy oil and gas company like Exxon.In early February we reported that Ubben was considering a \"meaningful stake\" in Exxon and could, as a result, even wind up with a seat on the board.Ubben left ValueAct last year to start his own firm that is focused on investments in social and environmental issues.","news_type":1,"symbols_score_info":{"XOM":0.9}},"isVote":1,"tweetType":1,"viewCount":2279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":361731476,"gmtCreate":1614261074895,"gmtModify":1704769779519,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmmm","listText":"hmmmm","text":"hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/361731476","repostId":"2114131201","repostType":4,"isVote":1,"tweetType":1,"viewCount":1632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":363979908,"gmtCreate":1614092302004,"gmtModify":1704888049741,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","text":"[OK] [OK] [OK] [OK]","images":[{"img":"https://static.tigerbbs.com/46e41ef5a75cec920506ef9f84aa63a2","width":"1080","height":"2157"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363979908","isVote":1,"tweetType":1,"viewCount":656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363945521,"gmtCreate":1614092225763,"gmtModify":1704888048449,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363945521","repostId":"363946391","repostType":1,"isVote":1,"tweetType":1,"viewCount":652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":353460824,"gmtCreate":1616513437568,"gmtModify":1704795188865,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","listText":"<a href=\"https://laohu8.com/S/MOGO\">$Mogo Finance Technology Inc.(MOGO)$</a>like me pls","text":"$Mogo Finance Technology Inc.(MOGO)$like me pls","images":[{"img":"https://static.tigerbbs.com/d1eabf3a50dad90af4a39bd7c5db8334","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353460824","isVote":1,"tweetType":1,"viewCount":2226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":364902905,"gmtCreate":1614789063307,"gmtModify":1704775350744,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>rest , ready to&nbsp;go","text":"$Tiger Brokers(TIGR)$rest , ready to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/364902905","isVote":1,"tweetType":1,"viewCount":1938,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341062059,"gmtCreate":1617762689971,"gmtModify":1704702790323,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>like my post old haha","text":"$Tiger Brokers(TIGR)$like my post old haha","images":[{"img":"https://static.tigerbbs.com/d6460bc8111d6b40363d22d3f8a2998a","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341062059","isVote":1,"tweetType":1,"viewCount":2115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":323944336,"gmtCreate":1615301275425,"gmtModify":1704780842618,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp; gogo","text":"[OK] [OK] [OK] gogo","images":[{"img":"https://static.tigerbbs.com/0186365c81b90e76d6a42357df7326ed","width":"1080","height":"2989"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323944336","isVote":1,"tweetType":1,"viewCount":1640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":371159511,"gmtCreate":1618922729333,"gmtModify":1704716907339,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/371159511","repostId":"2128947843","repostType":4,"repost":{"id":"2128947843","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1618914723,"share":"https://ttm.financial/m/news/2128947843?lang=&edition=fundamental","pubTime":"2021-04-20 18:32","market":"us","language":"en","title":"Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2128947843","media":"Benzinga","summary":"Johnson &amp; Johnson (NYSE:JNJ) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.34 by 10.68 percent. This is a 12.61 percent increase over earnings of $2.30 per share from the","content":"<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson Q1 Adj. EPS $2.59 Beats $2.34 Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-20 18:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Johnson &amp; Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.</p><p><b>Johnson &amp; Johnson Reports 2021 First-Quarter Results:</b></p><p><b>- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%</b></p><p><b>*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%</b></p><p><b>*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint</b></p><p><img src=\"https://static.tigerbbs.com/50a0fc781600445d28430e58a92ebbb1\" tg-width=\"646\" tg-height=\"289\" referrerpolicy=\"no-referrer\"></p><p><b><u>FIRST-QUARTER 2021 SEGMENT COMMENTARY:</u></b></p><p><b><u>Consumer Health</u></b></p><p>Consumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.&nbsp; Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.</p><p><b><u>Pharmaceutical</u></b></p><p>Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was&nbsp;partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.</p><p><b><u>Medical Devices</u></b></p><p>Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2128947843","content_text":"Johnson & Johnson, whose COVID-19 vaccine was put on pause last week to review reports of rare blood clots, reported $100 million in first-quarter sales of the shot on Tuesday and tightened its forecast for profits this year.Johnson & Johnson Reports 2021 First-Quarter Results:- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%*- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%*- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpointFIRST-QUARTER 2021 SEGMENT COMMENTARY:Consumer HealthConsumer Healthworldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.  Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.PharmaceuticalPharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, andU.S.ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.Medical DevicesMedical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2206,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3557227905112544","authorId":"3557227905112544","name":"ShaunVee","avatar":"https://static.tigerbbs.com/5f64fe4fcaa4f1d2aedde844df964cb4","crmLevel":11,"crmLevelSwitch":0,"idStr":"3557227905112544","authorIdStr":"3557227905112544"},"content":"Vaccine are here to stay, they gonna earn more money In near future i guess..","text":"Vaccine are here to stay, they gonna earn more money In near future i guess..","html":"Vaccine are here to stay, they gonna earn more money In near future i guess.."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":341976026,"gmtCreate":1617776262465,"gmtModify":1704702986356,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmm","listText":"hmmm","text":"hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/341976026","repostId":"1162389133","repostType":4,"isVote":1,"tweetType":1,"viewCount":2221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374051734,"gmtCreate":1619403768828,"gmtModify":1704723308172,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","listText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>how do you think this&nbsp;will going to how much in future 6mth?","text":"$Lion-OCBC Sec HSTECH S$(HST.SI)$how do you think this will going to how much in future 6mth?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374051734","isVote":1,"tweetType":1,"viewCount":2217,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884250657,"gmtCreate":1631896562979,"gmtModify":1676530665723,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884250657","repostId":"884264656","repostType":1,"isVote":1,"tweetType":1,"viewCount":2316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362819137,"gmtCreate":1614611789329,"gmtModify":1704773099898,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362819137","repostId":"1161689985","repostType":4,"isVote":1,"tweetType":1,"viewCount":2279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":361731476,"gmtCreate":1614261074895,"gmtModify":1704769779519,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"hmmmm","listText":"hmmmm","text":"hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/361731476","repostId":"2114131201","repostType":4,"isVote":1,"tweetType":1,"viewCount":1632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":363979908,"gmtCreate":1614092302004,"gmtModify":1704888049741,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","listText":"[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;[OK]&nbsp;","text":"[OK] [OK] [OK] [OK]","images":[{"img":"https://static.tigerbbs.com/46e41ef5a75cec920506ef9f84aa63a2","width":"1080","height":"2157"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363979908","isVote":1,"tweetType":1,"viewCount":656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363945521,"gmtCreate":1614092225763,"gmtModify":1704888048449,"author":{"id":"3570762430883798","authorId":"3570762430883798","name":"mavishhs","avatar":"https://static.tigerbbs.com/b49fbc4c03077f7d07a05e5bdadc632f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570762430883798","authorIdStr":"3570762430883798"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363945521","repostId":"363946391","repostType":1,"isVote":1,"tweetType":1,"viewCount":652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}